Skip to main content

Table 2 Characteristics of patients that initiated biologics, oral and SQ MTX in the previous 12 monthsa

From: Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis

  Biologic arm SQ MTX Oral MTX
N = 218 N = 49 N = 115
Biologic or novel small molecule initiated   n/a n/a
 Tocilizumab 13 (6.0)   
 Certolizumab 11 (5.1)
 Etanercept 51 (23.4)
 Adalimumab 53 (24.3)
 Abatacept 33 (15.1)
 Infliximab 22 (10.1)
 Rituximab 11 (5.1)
 Golimumab 13 (6.0)
 Tofacitinib 11 (5.1)
Frequency of MTX doses taken in last 4 weeks
 4 doses 133 (61.0) 31 (63.3) 90 (78.3)
 3 doses 7 (3.2) 1 (2.0) 9 (7.8)
 2 doses 10 (4.6) 1 (2.0) 5 (4.4)
 1 dose 1 (0.5) 2 (4.1) 2 (1.7)
 0 dosesb 66 (30.3) 14 (28.6) 9 (7.8)
 Not sure 1 (0.5) 0 (0.0) 0 (0.0)
Current MTX dose/week (mg)
 None 95 (43.5) 14 (28.6) 9 (8.0)
 Unknown 9 (4.1) 3 (6.1) 5 (4.4)
  < = 10 36 (16.5) 8 (16.3) 22 (19.1)
  > 10– < 20 42 (19.3) 7 (14.3) 44 (38.3)
  > =20 28 (12.8) 17 (34.7) 44 (38.3)
Reasons that patients missed 1 or more MTX doses in the last 4 weeksc N/A   
 Forgot   1 (2.0) 0 (0.0)
 Side effects 2 (4.1) 1 (0.9)
 Pharmacy shortage 1 (2.0) 0 (0.0)
 Doing well 1 (2.0) 1 (0.9)
 Couldn’t afford 1 (2.0) 1 (0.9)
 Other reasons 2 (4.1) 4 (3.5)
Willingness to pay for MTX N/A   
 $0   1 (2.0) 4 (3.5)
 $10 7 (14.3) 13 (11.3)
 Up to $25 19 (38.8) 34 (29.6)
 $25–$40 5 (10.2) 26 (22.6)
 $40–$80 2 (4.1) 6 (5.2)
Did injections hurt?    N/A
 No, never 55 (25.2) 11 (22.4)  
 Yes, rarely 34 (15.6) 14 (28.6)
 Yes, sometime 76 (34.9) 15 (30.6)
 Yes, often 53 (24.3) 9 (18.4)
  1. Data shown as n (%)
  2. n/a not asked
  3. ato avoid selection bias, patients did not need to continue MTX to be included in the two MTX arms of the survey; for this reason, not all patients are current users
  4. bThese are patients who reported that they were not currently taking MTX; they had discontinued at the time of the survey. However, some had recently discontinued and thus the counts are not synonymous with the “Current Dose = none” response
  5. cresponse among people who said they took only 1, 2, or 3 doses of MTX in the last 4 weeks